Semaglutide is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Ozempic (semaglutide) is FDA-approved for type 2 diabetes. This article covers mechanism, evidence base, FDA labeling, safety, and the upstream genetic variables — including TCF7L2, GLP1R, and FTO — that shape every type 2 diabetes decision.

Tirzepatide and semaglutide are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Semaglutide and tirzepatide are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Retatrutide and tirzepatide are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Trulicity (dulaglutide) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Zepbound (tirzepatide) was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. This article covers SURMOUNT-OSA trial outcomes, mechanism, safety, and the GLP-1 pathway genetics.

Semaglutide (semaglutide, marketed under multiple brand names (Ozempic, Wegovy, Rybelsus); also available through licensed compounding pharmacy pathways) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Retatrutide (retatrutide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Mounjaro (tirzepatide) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including GIPR, GLP1R, and FTO — that sit upstream of any decision.

Ozempic (semaglutide) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Wegovy (semaglutide) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Trulicity (dulaglutide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

GLP-1 — glucagon-like peptide-1 — is an incretin hormone. The GLP-1 receptor agonist drug class mimics it pharmacologically. This article covers GLP-1 hormone biology, how the drug class works, what's FDA-approved as of April 2026, and the GLP-1 pathway genetics including GLP1R, FTO, and MC4R.

Zepbound list price is approximately $1,059 per month at U.S. list price as of April 2026 (Eli Lilly published pricing). This article covers manufacturer savings programs, insurance coverage notes, compounded alternatives, and the PlexusDx Weight Management Protocols collection — all as of April 2026.

Semaglutide is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

GLP-1 receptor agonist medications (GLP-1 receptor agonists) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Rybelsus (oral semaglutide, Novo Nordisk) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Zepbound (tirzepatide) and Mounjaro (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Mounjaro list price is approximately $1,069 per month at U.S. list price as of April 2026 (Eli Lilly published pricing). This article covers manufacturer savings programs, insurance coverage notes, compounded alternatives, and the PlexusDx Weight Management Protocols collection — all as of April 2026.

Mounjaro (tirzepatide) and Zepbound (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Zepbound (tirzepatide) and Ozempic (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Semaglutide oral availability, FDA-approved oral GLP-1 options as of April 2026, how oral GLP-1 absorption works, cost, and the PlexusDx Semaglutide Oral and Tirzepatide Oral protocols inside the Weight Management Protocols collection.

Ozempic (semaglutide) and Mounjaro (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Mounjaro (tirzepatide) and Ozempic (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Zepbound (tirzepatide) and Wegovy (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Wegovy (semaglutide) and Zepbound (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Semaglutide has an FDA-approved dosing structure with graduated titration. This article covers the label-level dose range, administration format, and titration concept — clinical decisions belong with a qualified healthcare provider.

Wegovy (semaglutide) and Ozempic (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including FTO, GLP1R, and MC4R — that apply regardless of which compound is prescribed.

Retatrutide has an FDA-approved dosing structure with graduated titration. This article covers the label-level dose range, administration format, and titration concept — clinical decisions belong with a qualified healthcare provider.